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The emerging number of clinical trials in the gene therapy field poses the challenge to the industry to produce 
viral vectors in a scalable, reproducible and cost-efficient manner. To address this issue, our CAP-GT platform 
comprises high density, serum free suspension cell lines that enable reproducible, scalable transfection and 
high titer production of viral vectors. An adeno-associated virus (AAV) based vector was the first approved gene 
therapy product in clinical applications. Attractive features of AAV as a gene therapy vector are e.g. its lack of 
pathogenicity and its ability to transduce dividing and non-dividing cells. Moving away from mainly targeting 
ultra-rare diseases and taking more common indications into focus will need to see significant improvements 
concerning productivity and consistent quality of AAV vector production in order to ensure supply. For this 
purpose, we are developing a helper virus-free packaging cell line that can easily be turned into a producer cell 
line by only one additional step of cell line development. Base of this packing cell line is the generation of a cell 
line with stable Tet-inducible expression of Rep proteins. Extensive screening of Rep expressing single cell 
clones resulted in clonal cell lines which produced high AAV titers upon induction and transfection of the missing 
components. In a next step, the adenoviral helper functions E2A and E4orf6 are introduced, due to their toxicity 
also under the control of a Tet-inducible promoter. In addition, the VA RNA is encoded by the same construct. 
Finally, a Tet-inducible capsid function and GFP as transgene flanked by the ITRs combined on one construct 
will be stably integrated resulting in a proof of principle producer cell line. This approach should enable a 
consistent quality production of AAV vectors that abolishes the drawbacks of transient transfection concerning 
reproducibility, consistency and high costs for GMP-grade DNA. Process optimization in regard to process 
duration, feeding strategy etc. is currently ongoing for further improving the vector yields. 
 
